Healthcare & Hospital Management

Biography

Biography: Rana Moustafa

Abstract

Dapagliflozin is the second FDA approved agent in a new class of oral antihyperglycemic drugs, the sodium-glucose cotransporter 2 (SGLT2) inhibitors with innovative mechanisms of action. Managing diabetes mellitus (DM) with effective and tolerable oral agents will eventually decrease the devastating complications associated with the uncontrolled DM and ultimately improve the quality of life. This study aimed to assess the effectiveness of new oral antihyperglycemic drug Dapagliflozin in the treatment of type 2 DM as monotherapy or combination with other hypoglycemic agents in term of reduction in HbA1c and fasting blood glucose at 6, 9 and 12 months. In this retrospective study, all patients treated with Dapagliflozin in Hamad Medical Corporation (HMC) since its introduction as non-formulary medication on 1 April 2013 until 30th of April 2015 were included. Data regarding prescribed drugs were obtained from the computerized pharmacy system. Demographic information and laboratory results of patients have been achieved from the patient's electronic system (CERNER). Eighty-one patients were identified to receive Dapagliflozin during the study period, 71 % of them were males, and 100 % were Qataris with mean age 57 ± 9 years and mean A1C baseline 9 ± 1.4 %. Of note, all patients were receiving Dapagliflozin as add on therapy in combination with the standard therapy. Administration of Dapagliflozin as add-on therapy was found to decrease A1C significantly after 6 months by 0.8 (P=0.006), and after 12 months by 1.5 (P=0.062). Moreover, found to reduce the fasting blood significantly at 6 months and 9 months (P= 0.001, P=0.03 respectively). However, the coadministered antidiabetic medication did not influence the reduction in A1C or FBG. Dapagliflozin significantly reduced HbA1c level and the fasting blood glucose of type 2 diabetic patients in combination of other OHA or insulin within 6 to 12 months of treatment.